• 1
    Hruban RH, Pitman MB, Klimstra DS, eds. Tumors of the Pancreas. Atlas of Tumor Pathology, 4th Series, Fascicle 6. Washington, DC: American Registry of Pathology, Armed Forces Institutes of Pathology; 2007.
  • 2
    Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL. Cystic neoplasms of the pancreas. N Engl J Med. 2004; 351: 1218-1226.
  • 3
    Ohhashi K, Takagi K, Kato Y. Four cases of mucous secreting pancreatic cancer. Prog Dig Endosc. 1982; 20: 348-351.
  • 4
    Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008; 191: 802-807.
  • 5
    Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004; 28: 839-848.
  • 6
    Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006; 6: 17-32.
  • 7
    Adsay NV. Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg. 2008; 12: 401-404.
  • 8
    Adsay NV, Longnecker DS, Klimstra DS. Pancreatic tumors with cystic dilatation of the ducts: intraductal papillary mucinous neoplasms and intraductal oncocytic papillary neoplasms. Semin Diagn Pathol. 2000; 17: 16-30.
  • 9
    Egawa N, Mailleet B, Schroder S, Mukai K, Koppel G. Serous oligocystic and ill-demarcated adenoma of the pancreas: a variant of serous cystic adenoma. Virchows Arch. 1994; 424: 13-17.
  • 10
    Cizginer S, Turner B, Bilge AR, Karaca C, Pitman MB, Brugge WR. Cyst fluid carcinoembryonic antigen is an accurate diagnostic marker of pancreatic mucinous cysts. Pancreas. 2011; 40: 1024-1028.
  • 11
    Ahmad NA, Kochman ML, Brensinger C, et al. Interobserver agreement among endosonographers for the diagnosis of neoplastic versus non-neoplastic pancreatic cystic lesions. Gastrointest Endosc. 2003; 58: 59-64.
  • 12
    Genevay M, Mino-Kenudson M, Yaeger K, et al. Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts. Ann Surg. 2011; 254: 977-983.
  • 13
    Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C. Pancreatic cysts: preoperative diagnosis and clinical management. Cancer (Cancer Cytopathol). 2010; 118: 1-13.
  • 14
    Pitman MB, Genevay M, Yaeger K, et al. High-grade atypical epithelial cells in pancreatic mucinous cysts are a more accurate predictor of malignancy than “positive” cytology. Cancer (Cancer Cytopathol). 2010; 118: 434-440.
  • 15
    Pitman MB, Michaels PJ, Deshpande V, Brugge WR, Bounds BC. Cytological and cyst fluid analysis of small (≤3 cm) branch duct intraductal papillary mucinous neoplasms adds value to patient management decisions. Pancreatology. 2008; 8: 277-284.
  • 16
    Pitman MB, Deshpande V. Endoscopic ultrasound-guided fine needle aspiration cytology of the pancreas: a morphological and multimodal approach to the diagnosis of solid and cystic mass lesions. Cytopathology. 2007; 18: 331-347.
  • 17
    Sahani DV, Lin DJ, Venkatesan AM, et al. Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas. Clin Gastroenterol Hepatol. 2009; 7: 259-269.
  • 18
    Brugge WR. Role of endoscopic ultrasound in the diagnosis of cystic lesions of the pancreas. Pancreatology. 2001; 1: 637-640.
  • 19
    Brugge WR. Management and outcomes of pancreatic cystic lesions. Dig Liver Dis. 2008; 40: 854-859.
  • 20
    Wargo JA, Fernandez-del-Castillo C, Warshaw AL. Management of pancreatic serous cystadenomas. Adv Surg. 2009; 43: 23-34.
  • 21
    Adsay NV, Conlon KC, Zee SY, Brennan MF, Kilmstra DS. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer. 2002; 94: 62-77.
  • 22
    Crippa S, Fernandez-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010; 8: 213-219.
  • 23
    Crippa S, Salvia R, Warshaw AL, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg. 2008; 247: 571-579.
  • 24
    Yamao K, Yanaqisawa A, Takahashi K, et al. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan Pancreas Society. Pancreas. 2011; 40: 67-71.
  • 25
    Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011; 60: 1712-1720.
  • 26
    Chai SM, Herba K, Kumarasinghe MP, et al. Optimizing the multimodal approach to pancreatic cyst fluid diagnosis: developing a volume based triage protocol. Cancer (Cancer Cytopathol). 2013; 121: 86-100.
  • 27
    Shen J, Brugge WR, Dimaio CJ, Pitman MB. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer (Cancer Cytopathol). 2009; 117: 217-227.
  • 28
    Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004; 126: 1330-1336.
  • 29
    Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol. 2005; 3: 967-973.
  • 30
    Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009; 69: 1095-1102.
  • 31
    Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development [serial online]. Sci Transl Med. 2011; 3: 92ra66.
  • 32
    Agrawal D, Moparty B, Brugge WR. EUS-FNA cytology of pancreatic masses: performance characteristics improve with time (9 years) and experience (712 patients) [abstract]. Gastrointest Endosc. 2007; 65: AB306.
  • 33
    Ahmad NA, Kochman ML, Lewis JD, Ginsberg GG. Can EUS alone differentiate between malignant and benign cystic lesions of the pancreas? Am J Gastroenterol. 2001; 96: 3295-3300.
    Direct Link:
  • 34
    Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000; 95: 2271-2277.
    Direct Link:
  • 35
    Baba T, Yamaguchi T, Ishihara T, et al. Distinguishing benign from malignant intraductal papillary mucinous tumors of the pancreas by imaging techniques. Pancreas. 2004; 29: 212-217.
  • 36
    Bhutani MS. Role of endoscopic ultrasonography in the diagnosis and treatment of cystic tumors of the pancreas. JOP. 2004; 5: 266-272.
  • 37
    Brugge WR. The role of EUS in the diagnosis of cystic lesions of the pancreas. Gastrointest Endosc. 2000; 52(6 suppl): S18-S22.
  • 38
    Buscaglia JM, Giday SA, Kantsevoy SV, et al. Patient- and cyst-related factors for improved prediction of malignancy within cystic lesions of the pancreas. Pancreatology. 2009; 9: 631-638.
  • 39
    Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Pitman MB. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: cytohistologic analysis and correlation with histologic grade. Cancer (Cancer Cytopathol). 2006; 108: 163-173.
  • 40
    Pitman MB. Cytology of the pancreas. In: Gray W, Kocjan G, eds. Diagnostic Cytopathology. London, United Kingdom: Churchill Livingstone; 2010:333-366.